Trial Profile
A Phase 3 Study in Patients With Chronic Kidney Disease (CKD) With Hyperphosphatemia on Peritoneal Dialysis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Oct 2022
Price :
$35
*
At a glance
- Drugs Bixalomer (Primary)
- Indications Hyperphosphataemia; Renal failure
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 22 Dec 2014 New trial record